SCHEMBL4650783

SCHEMBL4650783

OB(O)c1ccc(F)c2c1OCO2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17662577 0.74 NPC1 (0.36)
SCHEMBL29950897 0.73 AOC3 (0.39)
SCHEMBL1224244 0.73 AOC3 (0.39)
SCHEMBL4650796 0.73 NPC1 (0.36)
SCHEMBL19121120 0.69 CTRC (0.31)
SCHEMBL21979683 0.69 AOC3 (0.36)
SCHEMBL19122860 0.68 ALDH1A1 (0.34)
SCHEMBL20900739 0.68
SCHEMBL962423 0.68 ABCG2 (0.44)
SCHEMBL17658864 0.68 MAPT (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
US-12264159-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2025-04-01 US disclosed
US-20240352023-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-10-24 US disclosed
US-20240262828-A1 Functionalized Heterocycles as Antiviral Agents ENANTA PHARM INC (US) 2024-08-08 US disclosed
US-12037338-B2 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-07-16 US disclosed
US-11891393-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-02-06 US disclosed
EP-3842436-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA SK BIOPHARMACEUTICALS CO LTD (KR) 2023-11-08 EP disclosed
US-20230075366-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS ENANTA PHARM INC (US) 2023-03-09 US disclosed
US-11198693-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2021-12-14 US disclosed
US-20210300933-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-09-30 US disclosed
US-20170349597-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-12-07 US disclosed
US-9745310-B2 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-08-29 US disclosed
US-20160251361-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-09-01 US disclosed
WO-2016137260-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-09-01 WO disclosed
US-20160137633-A1 PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES AJINOMOTO CO., INC. (JP) 2016-05-19 US disclosed
US-9290487-B2 Pharmaceutical composition for treating diabetes AJINOMOTO CO., INC. (JP) 2016-03-22 US disclosed
US-20140336376-A1 PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES AJINOMOTO CO., INC. (JP) 2014-11-13 US disclosed
EP-2774917-A1 PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES Ajinomoto Co., Inc. (JP) 2014-09-10 EP disclosed
EP-1971579-A1 2-(POLY-SUBSTITUTED ARYL)-6-AMINO-5-HALO-4-PYRIMIDINECARBOXYLIC ACIDS AND THEIR USE AS HERBICIDES Dow AgroSciences LLC (US) 2008-09-24 EP disclosed
WO-2007082076-A1 2-(POLY-SUBSTITUTED ARYL)-6-AMINO-5-HALO-4-PYRIMIDINECARBOXYLIC ACIDS AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2007-07-19 WO disclosed